Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expre… Read more
Arbutus Biopharma Corp - Asset Resilience Ratio
Arbutus Biopharma Corp (ABUS) has an Asset Resilience Ratio of 72.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2024)
This chart shows how Arbutus Biopharma Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Arbutus Biopharma Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $71.29 Million | 72.96% |
| Total Liquid Assets | $71.29 Million | 72.96% |
Asset Resilience Insights
- Very High Liquidity: Arbutus Biopharma Corp maintains exceptional liquid asset reserves at 72.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arbutus Biopharma Corp Industry Peers by Asset Resilience Ratio
Compare Arbutus Biopharma Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Arbutus Biopharma Corp (1998–2024)
The table below shows the annual Asset Resilience Ratio data for Arbutus Biopharma Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.52% | $86.29 Million | $131.71 Million | -3.54pp |
| 2023-12-31 | 69.06% | $99.72 Million | $144.40 Million | +9.63pp |
| 2022-12-31 | 59.43% | $116.14 Million | $195.42 Million | +36.92pp |
| 2021-12-31 | 22.51% | $46.03 Million | $204.49 Million | -29.29pp |
| 2020-12-31 | 51.81% | $71.02 Million | $137.08 Million | -4.13pp |
| 2019-12-31 | 55.94% | $59.03 Million | $105.53 Million | +17.47pp |
| 2018-12-31 | 38.47% | $87.67 Million | $227.91 Million | +8.07pp |
| 2017-12-31 | 30.40% | $72.10 Million | $237.20 Million | -8.42pp |
| 2016-12-31 | 38.82% | $107.10 Million | $275.90 Million | +36.78pp |
| 2015-12-31 | 2.04% | $14.53 Million | $712.29 Million | -31.80pp |
| 2014-12-31 | 33.84% | $40.00 Million | $118.20 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $71.72 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $52.60 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $13.70 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $21.02 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $41.95 Million | -- |
| 2008-12-31 | 11.12% | $4.71 Million | $42.34 Million | -- |
| 2007-12-31 | 0.00% | $0.00 | $24.83 Million | -- |
| 2006-12-31 | 0.00% | $0.00 | $6.03 Million | -- |
| 2005-12-31 | 0.00% | $0.00 | $18.50 Million | -- |
| 2004-12-31 | 0.00% | $0.00 | $41.10 Million | -- |
| 2003-12-31 | 7.19% | $3.65 Million | $50.73 Million | -26.00pp |
| 2002-12-31 | 33.20% | $17.67 Million | $53.22 Million | +0.76pp |
| 2001-12-31 | 32.44% | $21.93 Million | $67.60 Million | -34.98pp |
| 2000-12-31 | 67.41% | $21.93 Million | $32.52 Million | +37.18pp |
| 1999-12-31 | 30.24% | $8.71 Million | $28.80 Million | -5.51pp |
| 1998-12-31 | 35.75% | $5.66 Million | $15.83 Million | -- |